Alector Executive Compensation (FY25)
ALEC · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Arnon Rosenthal | Latest say-on-pay support = June 17, 2026 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Alector
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (8-K): June 17, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
233 figures on this page: 227 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
More on Alector
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Arnon Rosenthal: $3,666,341 → $1,995,018 (45.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Alector's chief executive and what were they paid?
Arnon Rosenthal was paid $1,995,018 in total compensation as Co-founder, Chief Executive Officer, and Director for fiscal 2025. Rosenthal's total was 45.6% lower than the $3,666,341 reported for fiscal 2024.
What was Alector's say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 95.9% support at the meeting held June 17, 2026.
Which companies are in Alector's peer group?
Companies named in the disclosed peer group include Acumen Pharmaceuticals, Inc., Assembly Biosciences, Inc., Boston, Gain Therapeutics, Inc. and Ovid Therapeutics Inc.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sara Kenkare-Mitra President and Head of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Marc Grasso Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gary Romano Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Arnon Rosenthal Co-founder, Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Arnon Rosenthal Co-founder, | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sara Kenkare-Mitra President and | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Marc Grasso Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gary Romano Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Arnon Rosenthal Co-founder, Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Sara Kenkare-Mitra President and Head of Research and Development | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Marc Grasso Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Gary Romano Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Arnon Rosenthal Co-founder, Chief Executive Officer, and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sara Kenkare-Mitra Former President and Head of Research and Development Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Neil Berkley Chief Financial Officer and Chief Business Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Arnon Rosenthal | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Arnon Rosenthal | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Arnon Rosenthal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Arnon Rosenthal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Neil Berkley | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Neil Berkley | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Neil Berkley | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Neil Berkley | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Neil Berkley | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sara Kenkare | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sara Kenkare | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Arnon Rosenthal | Option | ◇ | — | ◇ | 11/10/2035 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/1/2033 | |
| Option | ◇ | — | ◇ | 7/1/2035 | |
| Option | ◇ | — | ◇ | 10/1/2032 | |
| Neil Berkley | Option | ◇ | — | ◇ | 11/10/25 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 7/1/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/15/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Arnon Rosenthal
Co-founder, Chief Executive Officer, and Director · Terms as described in the company’s compensation discussion
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Neil Berkley
Chief Financial Officer and Chief Business Officer · Terms as described in the company’s compensation discussion
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Sara Kenkare-Mitra
Former President and Head of Research and Development · Terms as described in the company’s compensation discussion
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Richard H. Scheller | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Mark Altmeyer | ◇ | ◇ | ◇ | — | — | — | ◇ |
Errol De Souza | ◇ | ◇ | ◇ | — | — | — | ◇ |
Elizabeth Garofalo | ◇ | ◇ | ◇ | — | — | — | ◇ |
Paula Hammond | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kristine Yaffe | ◇ | ◇ | ◇ | — | — | — | ◇ |
David Wehner | ◇ | — | — | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as NSO and RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Acumen Pharmaceuticals, Inc. ABOS
- Assembly Biosciences, Inc. ASMB
- Boston BOC
- Gain Therapeutics, Inc. symbol not shown
- Ovid Therapeutics Inc. OVID
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 17, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 11, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 12, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 14, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 16, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 17, 2021 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Arnon Rosenthal (Co-founder, Chief Executive Officer, and Director), FY2025 total compensation $1,995,018 (base salary $678,100) [exec_comp, SEC accession 0001193125-26-186928, filed 2026-04-28]What this page does not include
Everything above is a fact Alector disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Alector sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
233 figures on this page: 227 cited to the filing that reported them, 6 calculated from figures it prints.
227 cited to the filing
6 calculated from the filing
Documents cited
- 0001193125-26-274130
- 0001193125-26-186928Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards
- 0001193125-25-245102Exhibit
- 0001193125-25-140731Exhibit · Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr.
- 0000950170-25-057991
- 0000950170-24-072512Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-048264
- 0001193125-23-167891Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-177617Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-21-000371Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Alector executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ALEC (accessed 2026).
Short form: data: Velarion
The paid brief for Alector
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Alector and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Alector discloses
The companies named in ALEC's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}